GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ZE46-0134
Compound class:
Synthetic organic
Comment: Lomonitinib is the INN for a tyrosine kinase inhibitor with antineoplastic potential. It appears to be the INN for Eilean Therapeutics' pan-FLT3/IRAK4 inhibitor (ZE46-0134) that is designed to simultaneously target clinically relevant resistance and activating FLT3 mutations and putative escape pathways (that arise via activation of IRAK4) in advanced AML [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Lomonitinib (ZE46-0134) is a clinical candidate for the treatment of relapsed/refractory AML with FLT3 mutations. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06366789 | Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 Interventional | Eilean Therapeutics | ||
| NCT06399315 | Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers | Phase 1 Interventional | Eilean Therapeutics | 1 | |